TLDR Standard Chartered projects XRP’s price could reach $8 by 2026 with a potential upside of 332% from its current price. The resolution of Ripple’s legal battleTLDR Standard Chartered projects XRP’s price could reach $8 by 2026 with a potential upside of 332% from its current price. The resolution of Ripple’s legal battle

XRP Price May Surge to $8 by 2026, Driven by Legal and ETF Growth

2025/12/30 21:07
3 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

TLDR

  • Standard Chartered projects XRP’s price could reach $8 by 2026 with a potential upside of 332% from its current price.
  • The resolution of Ripple’s legal battle with the U.S. SEC has reduced regulatory uncertainty surrounding XRP.
  • XRP’s market outlook is further strengthened by the launch of spot XRP ETFs, offering institutional investors regulated exposure.
  • The growing institutional interest in XRP has resulted in significant inflows into XRP ETFs, surpassing $1.24 billion in assets under management.
  • Ripple’s expanding payment network and real-world use in cross-border transactions are boosting XRP’s long-term value potential.

Standard Chartered has forecasted a significant price surge for XRP, projecting a potential increase to $8 by 2026. The bank attributes this outlook to the end of regulatory uncertainty and the rise of spot XRP ETFs. The forecast suggests a 332% upside from XRP’s current price of $1.85, signaling a favorable outlook for the digital asset.

Regulatory Clarity Drives XRP Price Surge

A primary factor behind Standard Chartered’s optimistic prediction is the resolution of the long-standing legal battle between Ripple and the U.S. SEC. In 2023, a court ruling stated that XRP’s programmatic sales on exchanges were not securities transactions. As the legal hurdles diminish, XRP’s market dynamics have been positively affected, giving institutional investors confidence to enter the space.

In August 2025, the legal proceedings officially ended following a change in U.S. government leadership and the appointment of a new SEC chair. Ripple and the SEC dropped their appeals, clearing the path for the cryptocurrency’s potential growth. Standard Chartered believes that this clarity will lead to a multi-year rally for XRP, as legal risks fade away.

Institutional Adoption and Spot XRP ETFs Fuel Growth

The introduction of spot XRP ETFs in the U.S. further bolsters XRP’s prospects. Asset managers like Canary, Franklin Templeton, and Grayscale have launched XRP products, giving institutional investors regulated exposure to the token. As of December 29, these ETFs had recorded $1.15 billion in net inflows, with a notable $8.44 million in new investments.

The assets under management for XRP ETFs have now surpassed $1.24 billion, signaling growing institutional interest. According to Standard Chartered, the increasing participation from institutional buyers is a strong catalyst for XRP’s price growth. The firm projects that if this momentum continues, XRP could surpass the $8 mark by 2026, with further potential to reach $10.5 by 2027.

With regulatory clarity and institutional backing, XRP’s price outlook is improving. The ongoing expansion of Ripple’s payment network across multiple countries and its real-world use in cross-border transactions further supports its long-term value. The convergence of these factors is expected to push XRP to higher valuations in the coming years.

The post XRP Price May Surge to $8 by 2026, Driven by Legal and ETF Growth appeared first on CoinCentral.

Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Vitalik Buterin to Ethereum Developers: Build It Like It Has to Last Without You

Key Takeaways Vitalik Buterin wants Ethereum apps built to survive without developers, corporate servers, or trusted third parties Two major […] The post Vitalik
Share
Coindoo2026/03/07 15:49
Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution

The post Non-Opioid Painkillers Have Struggled–Cannabis Drugs Might Be The Solution appeared on BitcoinEthereumNews.com. In this week’s edition of InnovationRx, we look at possible pain treatments from cannabis, risks of new vaccine restrictions, virtual clinical trials at the Mayo Clinic, GSK’s $30 billion U.S. manufacturing commitment, and more. To get it in your inbox, subscribe here. Despite their addictive nature, opioids continue to be a major treatment for pain due to a lack of effective alternatives. In an effort to boost new drugs, the FDA released new guidelines for non-opioid painkillers last week. But making these drugs hasn’t been easy. Vertex Pharmaceuticals received FDA approval for its non-opioid Journavx in January, then abandoned a next generation drug after a failed clinical trial earlier this summer. Acadia similarly abandoned a promising candidate after a failed trial in 2022. One possible basis for non-opioids might be cannabis. Earlier this year, researchers at Washington University at St. Louis and Stanford published a study showing that a cannabis-derived compound successfully eased pain in mice with minimal side effects. Munich-based pharmaceutical company Vertanical is perhaps the furthest along in this quest. It is developing a cannabinoid-based extract to treat chronic pain it hopes will soon become an approved medicine, first in the European Union and eventually in the United States. The drug, currently called Ver-01, packs enough low levels of cannabinoids (including THC) to relieve pain, but not so much that patients get high. Founder Clemens Fischer, a 50-year-old medical doctor and serial pharmaceutical and supplement entrepreneur, hopes it will become the first cannabis-based painkiller prescribed by physicians and covered by insurance. Fischer founded Vertanical, with his business partner Madlena Hohlefelder, in 2017, and has invested more than $250 million of his own money in it. With a cannabis cultivation site and drug manufacturing plant in Denmark, Vertanical has successfully passed phase III clinical trials in Germany and expects…
Share
BitcoinEthereumNews2025/09/18 05:26
Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

Short-term profit-taking pushes Bitcoin back below key $70K level – What next?

The post Short-term profit-taking pushes Bitcoin back below key $70K level – What next? appeared on BitcoinEthereumNews.com. Bitcoin [BTC] rallied as high as $74
Share
BitcoinEthereumNews2026/03/07 16:09